DNA-based vaccines against malaria: Status and promise of the Multi-Stage Malaria DNA Vaccine Operation

International Journal for Parasitology

Volumn 31, Issue 8, 2001, Pages 753-762

  Doolan, Denise L ^a,b   Hoffman, Stephen L ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trial; DNA vaccine; Immune enhancement; Malaria; Plasmodium; Prime boost

Indexed keywords

ADJUVANT; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; DOXYCYCLINE; GAMMA INTERFERON; HALOFANTRINE; MEFLOQUINE; PYRIMETHAMINE; RECOMBINANT PROTEIN; SULFADOXINE;

CLINICAL TRIAL; CODON; DRUG FATALITY; DRUG RESEARCH; ENDEMIC DISEASE; GASTROINTESTINAL SYMPTOM; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LIFE CYCLE; LYMPHOCYTOTOXICITY; MALARIA; MONKEY; NEUROLOGIC DISEASE; NONHUMAN; PLANNING; PLASMID; PLASMODIUM; POXVIRUS; REVIEW; VACCINATION;

ANIMALS; ANOPHELES; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; FEMALE; HAPLORHINI; HUMANS; INTERFERON TYPE II; MALARIA VACCINES; MALE; MICE; PLASMODIUM; RECOMBINANT PROTEINS; VACCINES, DNA;

ANIMALIA; POXVIRIDAE; PROTOZOA;

EID: 0034990655     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(01)00184-9     Document Type: Review

References (52)

1. Age-dependent characteristics of protection versus susceptibility to Plasmodium falciparum
2. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines
3. Genomic tool for gene and protein discovery in malaria: Toward new vaccines
4. Pathogenesis of malaria
5. + T cells in the Plasmodium yoelii model
6. The complexity of protective immunity against liver-stage malaria
7. Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1
8. + T cell, interferon-γ, and nitric oxide dependent immunity
9. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum
10. Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; comparisons and combinations
11. Immune effector mechanisms in malaria
12. Pathways and strategies for developing a malaria blood-stage vaccine
13. Optimization of antibody responses to a Plasmodium falciparum DNA vaccine in Aotus monkeys
14. Malaria DNA vaccines in Aotus monkeys
15. Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunisation protocol
16. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
17. In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines
18. Research (genomics) is crucial to attacking malaria
19. The Plasmodium falciparum infected hepatocyte as a target for vaccine-induced immune responses
20. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunisation?
21. Attacking the infected hepatocyte
22. From genomics to vaccines: Malaria as a model system
23. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 Region II DNA prime-boost immunisation regimen
24. Engineering of in vivo immune responses to DNA immunisation via codelivery of costimulatory molecule genes
25. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
26. Indicators of life-threatening malaria in African children
27. Plasmid DNA malaria vaccine: The potential for genomic integration following intramuscular injection
28. Malaria pathogenesis
29. + responses in mice
30. Pre-erythrocytic malaria vaccine: Mechanisms of protective immunity and human vaccine trials
31. Rationale for the development of an engineered sporozoite malaria vaccine
32. Plasmid DNA malaria vaccine: Tissue distribution and safety studies in mice and rabbits
33. An antitoxic vaccine for malaria?
34. The immunology of malaria infection
35. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
36. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
37. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunisations
38. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens
39. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
40. + T cells using heterologous prime-boost immunisation strategies
41. Protection against malaria by immunisation with plasmid DNA encoding circumsporozoite protein
42. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
43. Improving protective immunity induced by DNA-based immunisation: Priming with antigen and GM-CSF encoding plasmid DNA and boosting with antigen expressing recombinant poxvirus
44. New insights into the epidemiology of malaria relevant for disease control
45. The conserved genome organisation of non-falciparum malaria species: The need to know more
46. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunisation with a mixture of four Plasmodium falciparum DNA plasmids
47. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
48. DNA vaccination strategies against infectious diseases
49. + T cells (cytotoxic/suppressors) are required for protection in mice immunised with malaria sporozoites
50. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine